(Q36711574)

15 August 2017

1 reference

title

Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic (English)

1 reference

15 August 2017

0 references

Plosker GL

1

1 reference

15 August 2017

Goa KL

series ordinal

2

1 reference

15 August 2017

publication date

1 November 1991

1 reference

15 August 2017

1 reference

15 August 2017

volume

42

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

805-824

1 reference

Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation.

15 August 2017

cites work

1 reference

12 December 2020

Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group

1 reference

12 December 2020

An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy

1 reference

12 December 2020

Extrapyramidal reactions with high-dose metoclopramide

1 reference

12 December 2020

A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response

1 reference

12 December 2020

Identification and distribution of 5-HT3 recognition sites within the human brainstem.

1 reference

12 December 2020

Behavioural pharmacology of 5-HT3 receptor ligands

1 reference

12 December 2020

5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue

1 reference

12 December 2020

A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group

1 reference

12 December 2020

The emetic activity of centrally administered cisplatin in cats and its antagonism by zacopride

1 reference

12 December 2020

A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group

1 reference

12 December 2020

Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility

1 reference

12 December 2020

Ondansetron. Therapeutic use as an antiemetic

1 reference

12 December 2020

Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects

1 reference

12 December 2020

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone

1 reference

12 December 2020

Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding

1 reference

12 December 2020

Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve

1 reference

12 December 2020

Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain

1 reference

12 December 2020

Differential effect of typical and atypical antipsychotic drugs on the suppressant action of 2-methylserotonin on medical prefrontal cortical cells: a microiontophoretic study

1 reference

12 December 2020

A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group

1 reference

12 December 2020

Effects of 5-hydroxytryptamine 3 receptor antagonists on gastrointestinal motor activity in conscious dogs

1 reference

12 December 2020

5-Hydroxytryptamine receptor subtypes

1 reference

12 December 2020

Granisetron (BRL 43694) in the treatment of cytostatic drug-induced emesis: a summary

1 reference

12 December 2020

5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret

1 reference

12 December 2020

Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting

1 reference

12 December 2020

The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist

1 reference

12 December 2020

The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret

1 reference

12 December 2020

Safety of ondansetron

1 reference

12 December 2020

Controlled clinical studies of orally administered antiemetic drugs.

1 reference

12 December 2020

Neuroactive substances in the dorsal vagal complex of the medulla oblongata: nucleus of the tractus solitarius, area postrema, and dorsal motor nucleus of the vagus

1 reference

12 December 2020

The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis.

1 reference

12 December 2020

Blockade of serotonin receptors on autonomic neurones by (−)-cocaine and some related compounds

1 reference

12 December 2020

Study of the contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea-pig ileum. Evidence for two distinct release mechanisms.

1 reference

12 December 2020

Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron).

1 reference

12 December 2020

The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension

1 reference

12 December 2020

Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species

1 reference

12 December 2020

High versus low dose granisetron, a selective 5HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine

1 reference

12 December 2020

The 5-HT3 receptor ligand, [3H]BRL 43694, binds to presynaptic sites in the nucleus tractus solitarius of the rat

1 reference

12 December 2020

First Clinical Study of the Selective 5-HT3 Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache

1 reference

12 December 2020

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

1 reference

12 December 2020

Detection of a novel serotonin receptor subtype (5-HT1E) in human brain: interaction with a GTP-binding protein

1 reference

12 December 2020

Neuropharmacology of emesis induced by anti-cancer therapy.

1 reference

12 December 2020

Clinical studies with ondansetron in the control of radiation-induced emesis.

1 reference

12 December 2020

Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism

1 reference

12 December 2020

Evidence for presynaptic 5-hydroxytryptamine3 recognition sites on vagal afferent terminals in the brainstem of the ferret

1 reference

12 December 2020

Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine

1 reference

12 December 2020

Effects of granisetron and lorazepam, alone and in combination, on psychometric performance

1 reference

12 December 2020

Identification and characterisation of 5-hydroxytryptamine 3 recognition sites in human brain tissue.

1 reference

12 December 2020

The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.

1 reference

12 December 2020

Antagonism of the effects of 5-hydroxytryptamine on the rabbit isolated vagus nerve by BRL 43694 and metoclopramide

1 reference

12 December 2020

Localization of 5-HT3 receptor binding sites in human dorsal vagal complex

1 reference

12 December 2020

Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity

1 reference

12 December 2020

A primer on geriatric psychopharmacology

1 reference

12 December 2020

[3H]-BRL 43694 (Granisetron), a specific ligand for 5-HT3 binding sites in rat brain cortical membranes

1 reference

12 December 2020

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

The symptomatic control of cytostatic drug-induced emesis. A recent history and review

1 reference

12 December 2020

Cisplatin-induced emesis in the Ferret: a new animal model

1 reference

12 December 2020

Optimum management of nausea and vomiting in cancer chemotherapy

1 reference

12 December 2020

Is there a relationship between serotonin receptor subtypes and selectivity of response in specific psychiatric illnesses?

1 reference

12 December 2020

Combination antiemetics for cisplatin chemotherapy

1 reference

12 December 2020

The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis

1 reference

12 December 2020

Identification of 5-HT3 recognition sites in the ferret area postrema

1 reference

12 December 2020

Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.

1 reference

12 December 2020

10.2165/00003495-199142050-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1043863811

0 references

1 reference